Global Intrauterine Contraceptive Devices (IUD) Market - Growth, Trends and Forecasts (2017 - 2022)

The Global Intra Uterine contraceptive Devices market is estimated to be USD 1,370 million in 2016 and is expected to reach USD 2,267 million by 2021, growing at a compound annual growth rate (CAGR) of 10.6% during the forecast period of 2016 to 2021.

IUDs are small contraceptive devices, often T-shaped, containing either copper or levonorgestrel, which are inserted into the uterus. They are a form of long-acting contraception and are the most effective type of reversible birth control.

Global IUD Market- Market Dynamics

The report details several factors driving and restraining the global market for IUDs. The opportunities and challenges for the market are also discussed. Some of these are listed below.


Technological innovations

Increase in the prevalence of Sexually Transmitted Diseases (STD)

Pregnancy prevention

Immediate health benefits other than birth control

Rise in government initiatives to prevent unwanted abortions and pregnancies


Cultural or religious oppositions prevalent in many countries

Limited access to contraception

Infertility issues

Economic constraints

Opportunities and Challenges

The new products that are in the research pipeline and the belief that IUDs are the safest contraceptives are some of the market opportunities for the key players. However, they also face the challenge of dealing with the threat of Pelvic Inflammatory Infection (PFD) and ectopic pregnancy as a result of the use of IUDs.

The global IUD market is broadly segmented based on the type and product. Based on the type, the market is further segmented into hormonal intrauterine device and copper intrauterine device market. Based on the product, the market is segmented into MIRENA, SKYLA, PARAGARD, ESSURE, LEVOSERT and others.

Based on geographical location, the intrauterine device market can be divided into North America (the USA, Canada, and Mexico), Europe (France, UK, Germany, Spain, Portugal, Scandinavia and Italy), Asia-Pacific (India, China, Japan, South Korea, Australia, and New Zealand), Middle East and Africa (GCC, Egypt) and Latin America (Brazil and Argentina).

Some of the key players in the market are:

Agile Therapeutics

Actavis PLC

ANI Pharmaceuticals, Inc.

Church & Dwight, Co. Inc.

Fuji Latex Co., Ltd

Johnson & Johnson, Ltd

Lupin Pharmaceuticals, Ltd

Okamato Industries, Inc.


Key Deliverables in the Study

Market analysis for the Intra Uterine Devices Market, with global and region-specific assessments and competition analysis on the global and regional scale.

Market definition along with the identification of key drivers and restraints

Identification of factors instrumental in changing the market scenario, rising prospective opportunities, and identification of key companies that can influence this market on a global and regional scale.

Extensively researched competitive landscape section with profiles of major companies along with their market share.

Identification and analysis of the macro and micro factors that affect the intrauterine device market on both global and regional scale.

A comprehensive list of key market players along with the analysis of their current strategic interests and key financial information.

A wide-ranging knowledge and insights about the major players in this industry and the key strategies adopted by them to sustain and grow in the studied market.

Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped.


1.1 Study deliverables

1.2 Market Definition

1.3 Sizing Units

1.4 Base Currency

1.5 Review and forecast period years

1.6 General Study Assumptions


2.1 Introduction

2.2 Analysis Methodology

2.3 Econometric forecast models

2.4 Research Assumptions




5.1 Current market scenario

5.2 Technology Overview

5.3 New developments in therapeutics

5.4 Investment analysis

5.5 PorterFive Force Analysis

5.5.1 Bargaining Power of suppliers

5.5.2 Bargaining power of buyers

5.5.3 Degree of competition

5.5.4 Threat of substitution

5.5.5 Threat of new entrants


6.1 Market Drivers

6.1.1 Technological Innovation

6.1.2 Increasing rate of STD

6.1.3 Pregnancy prevention

6.1.4 Immediate Health benefits other than birth control

6.1.5 Rise in Government initiatives to prevent unwanted abortions and pregnancies

6.2 Market Restraints

6.2.1 Cultural or Religious opposition

6.2.2 Limited access to contraception

6.2.3 Infertility issues

6.2.4 Economic constraints

6.3 Market Opportunities

6.3.1 New product pipelines

6.3.2 Safest option as compared to others present in the market

6.4 Key Challenges

6.4.1 Threat of causing Pelvic Inflammatory Infection (PID)

6.4.2 Threat of causing ectopic pregnancy

7. Global Intra Uterine Device Segmentation

7.1 By type

7.1.1 Hormonal Intra uterine device

7.1.2 Copper Intra uterine device

7.2 By products

7.2.1 MIRENA

7.2.2 SKYLA


7.2.4 ESSURE


7.2.6 Others

8. Global Intra Uterine Device Market by Geography - Regional shares and forecast

8.1 North America

8.1.1 Introduction

8.1.2 USA

8.1.3 Canada

8.1.4 Mexico

8.1.5 Rest of North America

8.2 Europe

8.2.1 Introduction

8.2.2 France

8.2.3 UK

8.2.4 Germany

8.2.5 Spain and Portugal

8.2.6 Scandinavia

8.2.7 Italy

8.2.8 Rest of Europe

8.3 Asia-Pacific

8.3.1 Introduction

8.3.2 India

8.3.3 China

8.3.4 Japan

8.3.5 South Korea

8.3.6 Australia and New Zealand

8.3.7 Rest of Asia-Pacific

8.4 Middle East and Africa

8.4.1 Introduction

8.4.2 GCC

8.4.3 Egypt

8.4.4 Rest of Middle East and Africa

8.5 Latin America

8.5.1 Introduction

8.5.2 Brazil

8.5.3 Argentina

8.5.4 Rest of Latin America


9.1 Mergers & Acquisitions

9.2 New Product Launches

9.3 Agreements, Collaborations & Partnerships


10.1 Bayer Healthcare

10.2 Pfizer

10.3 Merck & Co.

10.4 Teva Pharmaceuticals, Ltd.

10.5 Agile Therapeutics

10.6 Actavis PLC

10.7 ANI Pharmaceuticals, Inc.

10.8 Church & Dwight, Co. Inc.

10.9 Fuji Latex Co., Ltd

10.10 Johnson & Johnson, Ltd

10.11 Lupin Pharmaceuticals, Ltd

10.12 Okamato Industries, Inc.

10.13 Reckitt Benckiser Group, PLC

10.14 The Female Health Company

10.15 Mylan Laboratories

11. Analyst outlook for Investment Opportunities

12. Future outlook of the market


13.1 Abbreviations

13.2 Bibliography

13.3 Disclaimer

Content are not available

Choose License Type